Showing 15 posts of 39 posts found.

American Heart Association awards $2.1m to research link between migraine, strokes and CVD

July 27, 2023
Research and Development American Heart Association, Cardiology, cvd, migraine, stroke

The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

June 2, 2023
Medical Communications NHS, NICE, Neurology, Pfizer, migraine

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended an oral treatment for the …


New study challenges link between stress and migraines

January 25, 2021
Sales and Marketing Curelator, migraine

Digital health platform Curelator has announced new data that shows a lack of association between increased stress and migraine attacks. …

NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine

December 11, 2020
Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine

NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …

Axsome’s late-stage study of experimental depression drug misses main trial goal

March 31, 2020
Manufacturing and Production Depressive Disorder, MDD, depression, migraine

Axsome Therapeutics reported on Monday that its Phase 3 study of its experimental depression drug missed its main trial goal. …


Teva’s Ajovy becomes first drug of its kind available on NHS for prevention of chronic migraine

March 12, 2020
Sales and Marketing NICE, Teva, ajovy, migraine, pharma

NICE has announced the authorisation of Teva’s anti-CGRP drug Ajovy (fremanezumab) for the prevention of chronic migraine in adult patients …

Lundbeck’s Vyepti secures US approval for migraine prevention

February 24, 2020
Sales and Marketing FDA, Lundbeck, Vyepti, migraine, pharma

Lundbeck’s Vyepti (eptinezumab-jjmr) has secured approval from the FDA, it has emerged, for the prevention of migraine in adult patients. …


FDA approves Teva’s Ajovy autoinjector for treatment of migraine

January 29, 2020
Research and Development, Sales and Marketing FDA, Teva, ajovy, migraine, pharma

Israeli pharma firm Teva has revealed that the FDA has chosen to award approval to its autoinjector device for the …

Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine

October 15, 2019
Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma

Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …

NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland

September 26, 2019
Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma

NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …

Lundbeck acquires Alder in $2bn migraine treatment move

September 16, 2019
Sales and Marketing Alder, Lundbeck, eptinezumab, migraine

Lundbeck is to buy Alder Biopharmaceuticals for $2 billion enhancing its leading portfolio of brain disease therapies through the acquisition …


4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine

September 9, 2019
Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma

Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …

Pfizer recall two batches of migraine drug Relpax

August 16, 2019
Medical Communications FDA, Pfizer, Relpax, migraine, pharma, recall

Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination. In a statement on the …


Lilly’s Emgality smashes all Phase 3 endpoints in migraine sub-population

August 6, 2019
Manufacturing and Production, Research and Development Eli Lilly, Emgality, migraine, pharma

New Phase 3 data have been revealed on Eli Lilly’s Emgality (galcanezumab-gnlm), detailing its success in meeting all of its …


Biohaven’s CGPR antagonist migraine treatment beats placebo in Phase 3 trial

July 11, 2019
Research and Development Biohaven, CGPR, clinical trials, headache, migraine, pharma

Connecticut-based firm Biohaven has said its migraine drug rimegepant showed superiority over placebo in a Phase 3 clinical trial. The …

Latest content